- Home
- LSTA vs ANEB Comparison
LSTA vs ANEB Comparison
Compare LSTA & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- ANEB
- Stock Information
- Founded
- LSTA 1980
- ANEB 2020
- Country
- LSTA United States
- ANEB United States
- Employees
- LSTA N/A
- ANEB N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- ANEB Health Care
- Exchange
- LSTA Nasdaq
- ANEB Nasdaq
- Market Cap
- LSTA 20.9M
- ANEB 111.8M
- IPO Year
- LSTA N/A
- ANEB 2021
- Fundamental
- Price
- LSTA $2.31
- ANEB $2.50
- Analyst Decision
- LSTA Strong Buy
- ANEB Buy
- Analyst Count
- LSTA 2
- ANEB 2
- Target Price
- LSTA $23.50
- ANEB $8.00
- AVG Volume (30 Days)
- LSTA 140.1K
- ANEB 21.4K
- Earning Date
- LSTA 11-06-2025
- ANEB 11-14-2025
- Dividend Yield
- LSTA N/A
- ANEB N/A
- EPS Growth
- LSTA N/A
- ANEB N/A
- EPS
- LSTA N/A
- ANEB N/A
- Revenue
- LSTA $1,070,000.00
- ANEB N/A
- Revenue This Year
- LSTA N/A
- ANEB N/A
- Revenue Next Year
- LSTA N/A
- ANEB N/A
- P/E Ratio
- LSTA N/A
- ANEB N/A
- Revenue Growth
- LSTA N/A
- ANEB N/A
- 52 Week Low
- LSTA $1.87
- ANEB $0.80
- 52 Week High
- LSTA $4.20
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- LSTA 41.59
- ANEB 45.45
- Support Level
- LSTA $2.00
- ANEB $2.44
- Resistance Level
- LSTA $2.98
- ANEB $2.65
- Average True Range (ATR)
- LSTA 0.23
- ANEB 0.09
- MACD
- LSTA -0.03
- ANEB -0.03
- Stochastic Oscillator
- LSTA 31.63
- ANEB 14.63
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.